ES2059965T3 - Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias. - Google Patents

Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.

Info

Publication number
ES2059965T3
ES2059965T3 ES90123628T ES90123628T ES2059965T3 ES 2059965 T3 ES2059965 T3 ES 2059965T3 ES 90123628 T ES90123628 T ES 90123628T ES 90123628 T ES90123628 T ES 90123628T ES 2059965 T3 ES2059965 T3 ES 2059965T3
Authority
ES
Spain
Prior art keywords
inflammatory diseases
treatment
pharmaceutical composition
preparing
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90123628T
Other languages
English (en)
Inventor
Kenichi Iwamitsu
Yukio Nakamura
Masahiro Kawasaki
Yoshio Fukui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissho Corp
Original Assignee
Nissho Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18278891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2059965(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissho Corp filed Critical Nissho Corp
Application granted granted Critical
Publication of ES2059965T3 publication Critical patent/ES2059965T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA PARA TRATAR ENFERMEDADES INFLAMATORIAS, COMPRENDE (A) UNA CANTIDAD EFECTIVA DE ACIDO HIALURONICO O SUS SALES, Y (B) UNA CANTIDAD EFECTIVA DE UN AGENTE ANTI-INFLAMATORIO. LA COMPOSICION PRODUCE UN EFECTO TERAPEUTICO SINERGISTICO EN INFLAMACIONES Y ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, EN PARTICULAR DE ENFERMEDADES DE ARTICULACION CON INFLAMACION.
ES90123628T 1989-12-21 1990-12-08 Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias. Expired - Lifetime ES2059965T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33457189 1989-12-21

Publications (1)

Publication Number Publication Date
ES2059965T3 true ES2059965T3 (es) 1994-11-16

Family

ID=18278891

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90123628T Expired - Lifetime ES2059965T3 (es) 1989-12-21 1990-12-08 Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.

Country Status (7)

Country Link
US (1) US5095037B1 (es)
EP (1) EP0433817B1 (es)
CA (1) CA2031880C (es)
DE (1) DE69003229T2 (es)
ES (1) ES2059965T3 (es)
FI (1) FI906249A (es)
NO (1) NO177525C (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5817642A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Clearing of atherosclerosis
CA2122551A1 (en) * 1994-04-29 1995-10-30 Rudolf Edgar Falk Clearing of atherosclerosis
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2112751A1 (en) * 1991-07-03 1993-01-21 Charles J. Ii Betlach Composition and method for transdermal delivery of diclofenac
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US5847002A (en) * 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
CA2094203A1 (en) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
GB9425487D0 (en) 1994-12-16 1995-02-15 Res Inst Osteoarthritis treatment
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US20030008396A1 (en) * 1999-03-17 2003-01-09 Ku David N. Poly(vinyl alcohol) hydrogel
DE60036915T2 (de) 1999-01-13 2008-08-07 Alchemia Oncology Pty Ltd., Hawthorn Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
US6645485B2 (en) * 2000-05-10 2003-11-11 Allan R. Dunn Method of treating inflammation in the joints of a body
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
WO2002051442A1 (fr) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Co-prescriptions
ATE417617T1 (de) * 2001-03-15 2009-01-15 Seikagaku Kogyo Co Ltd Mittel zur steurung der expression von il-12
WO2003000190A2 (en) * 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
RU2303447C2 (ru) * 2001-08-30 2007-07-27 Меркле Гмбх Применение аннелированных соединений пиррола при лечении дегенерации суставного хряща или структурных изменений субхондральной кости
US20050142208A1 (en) * 2002-05-09 2005-06-30 Won Min Yoo Pharmceutical composition for treatment of wounds conntaining blood plasma or serum
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
EP1747006B1 (en) * 2004-01-20 2009-07-01 Panacea Biotec Ltd. Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug
CA2558623C (en) 2004-02-06 2013-04-16 Georgia Tech Research Corporation Surface directed cellular attachment
AU2005212339B2 (en) * 2004-02-06 2010-11-25 Georgia Tech Research Corporation Load bearing biocompatible device
US7956180B2 (en) * 2004-05-27 2011-06-07 Novozymes A/S Dried and agglomerated hyaluronic acid product
CA2567722C (en) * 2004-05-27 2013-06-18 Novozymes Biopolymer A/S A dried and agglomerated hyaluronic acid product
US20050278025A1 (en) * 2004-06-10 2005-12-15 Salumedica Llc Meniscus prosthesis
WO2006039704A2 (en) * 2004-09-30 2006-04-13 Janssen Pharmaceutica, N.V. Pharmaceutical composition and method for treating a joint capsule arthropathy
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
WO2007028196A1 (en) * 2005-09-07 2007-03-15 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
EP2063859B1 (en) * 2006-09-13 2017-01-18 Enhance Skin Products Inc. Cosmetic composition for the treatment of skin and methods thereof
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
FR2918276B1 (fr) * 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
FR2918476B1 (fr) * 2007-07-02 2012-08-03 Experts Enlargement Quality Exeq Controle de conformite de donnees.
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US8178511B1 (en) * 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
FR2945949B1 (fr) * 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.
IL206739A (en) * 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
TWI382841B (zh) * 2010-10-29 2013-01-21 Univ China Medical 用於抑制發炎之醫藥組合物
EA201390099A1 (ru) 2011-05-26 2013-05-30 Картива, Инк. Конический суставный имплант и относящиеся к нему инструменты
EP2543357B1 (en) * 2011-07-07 2018-03-21 Holy Stone Healthcare Co.,Ltd. Composition for use in treating and preventing inflammation related disorder
US10350072B2 (en) 2012-05-24 2019-07-16 Cartiva, Inc. Tooling for creating tapered opening in tissue and related methods
US10758374B2 (en) 2015-03-31 2020-09-01 Cartiva, Inc. Carpometacarpal (CMC) implants and methods
US9907663B2 (en) 2015-03-31 2018-03-06 Cartiva, Inc. Hydrogel implants with porous materials and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
CA1327354C (en) * 1987-03-19 1994-03-01 David Cullis-Hill Anti-inflamatory compounds and compositions

Also Published As

Publication number Publication date
NO177525B (no) 1995-06-26
EP0433817B1 (en) 1993-09-08
CA2031880A1 (en) 1991-06-22
NO905514L (no) 1991-06-24
NO177525C (no) 2000-09-07
FI906249A (fi) 1991-06-22
US5095037B1 (en) 1995-12-19
EP0433817A1 (en) 1991-06-26
CA2031880C (en) 1999-09-21
FI906249A0 (fi) 1990-12-18
NO905514D0 (no) 1990-12-20
US5095037A (en) 1992-03-10
DE69003229D1 (de) 1993-10-14
DE69003229T2 (de) 1994-04-14

Similar Documents

Publication Publication Date Title
ES2059965T3 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.
BR9707325A (pt) Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
DK0607128T3 (da) Lægemiddel samt fremstilling deraf og anvendelse deraf ved bekæmpelsen af smerter og/eller betændelser hos dyr og mennesker
ES2186693T3 (es) Uso combinado del acido hialuronico y de agentes terapeuticos para mejorar el efecto terapeutico.
ES2164097T3 (es) Uso de anestesicos topicos para la fabricacion de un medicamento para el tratamiento del asma bronquial.
PT1086702E (pt) Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
NO981392L (no) Substituerte pyrazolylbenzensulfonamider for anvendelse i veterinµrterapi som antiinflammatorisk middel
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
GEP20022656B (en) 2-(Purin-9-YL)-Tetrahydrofuran-3,4-Diol Derivatives
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
ATE39323T1 (de) Injizierbare loesung zur behandlung von entzuendungen.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
PT99597B (pt) Processo para a preparacao de derivados do acido hidroxamico que inibem a lipoxigenase
AU4786290A (en) The use of the active substance azelastine in combatting psoriasis disorders and inflammatory disorders
ES2090317T3 (es) Uso del acido 3-guanidinopropionico en la fabricacion de un medicamento para el tratamiento y prevencion del exceso de adiposidad.
ES2061989T3 (es) Uso de esteres alquilicos del acido piroglutamico para la fabricacion de un medicamento para el tratamiento de la ictiosis.
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
MX9400630A (es) 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida como un agente analgesico y antiinflamatorio.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.
ES2091031T3 (es) Uso de acido hialuronico para prevenir la reestenosis arterial.
IE870577L (en) Topical amide preparation
AR010432A1 (es) Composiciones farmaceuticas que contienen acido ricinoleico y su uso para la terapia antiinflamatoria y analgesica
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 433817

Country of ref document: ES